Difference between revisions of "Osimertinib (Tagrisso)"
Jump to navigation
Jump to search
m (Text replacement - "[[Media:" to "[[File:") |
Warner-admin (talk | contribs) m (Text replacement - "[http://online.lexi.com/ Lexicomp]" to "Lexicomp") |
||
| (14 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Mutant-selective EGFR tyrosine kinase inhibitor. Osimertinib preferentially binds irreversibly to certain mutant forms of the epidermal growth factor receptor (EGFR) (T790M, L858R, and exon 19 deletion) at approximately 9-times lower concentrations than wild-type. Two pharmacologically-active metabolites of osimertinib, AZ7550 and AZ5104, also emerge at about 10% the level of osimertinib. AZ7550 had similar potency to osimertinib. AZ5104 had about 8-times greater potency against exon 19 deletion and T790M mutants than osimertinib and 15-times greater potency against wild-type EGFR. Osimertinib also inhibits activity of HER2, HER3, HER4, ACK1, and BLK.<ref name=insert>[http://www.azpicentral.com/tagrisso/tagrisso.pdf Osimertinib (Tagrisso) package insert]</ref><ref>[[File:Osimertinib.pdf | Osimertinib (Tagrisso) package insert (locally hosted backup)]]</ref><ref>[https://www.tagrisso.com/ Tagrisso manufacturer's website]</ref> | + | Class/mechanism: Mutant-selective EGFR tyrosine kinase inhibitor. Osimertinib preferentially binds irreversibly to certain mutant forms of the epidermal growth factor receptor (EGFR) (T790M, L858R, and exon 19 deletion) at approximately 9-times lower concentrations than wild-type. Two pharmacologically-active metabolites of osimertinib, AZ7550 and AZ5104, also emerge at about 10% the level of osimertinib. AZ7550 had similar potency to osimertinib. AZ5104 had about 8-times greater potency against exon 19 deletion and T790M mutants than osimertinib and 15-times greater potency against wild-type EGFR. Osimertinib also inhibits activity of HER2, HER3, HER4, ACK1, and BLK.<ref name=insert>[http://www.azpicentral.com/tagrisso/tagrisso.pdf Osimertinib (Tagrisso) package insert]</ref><ref>[[:File:Osimertinib.pdf | Osimertinib (Tagrisso) package insert (locally hosted backup)]]</ref><ref>[https://www.tagrisso.com/ Tagrisso manufacturer's website]</ref> |
<br>Route: PO | <br>Route: PO | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> |
==Resistance mechanisms== | ==Resistance mechanisms== | ||
| − | *'''2019:''' Leonetti et al. [https:// | + | *'''2019:''' Leonetti et al. [https://doi.org/10.1038/s41416-019-0573-8 Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer] |
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| Line 14: | Line 14: | ||
==Patient drug information== | ==Patient drug information== | ||
*[http://www.azpicentral.com/tagrisso/tagrisso.pdf Osimertinib (Tagrisso) package insert]<ref name="insert"></ref> | *[http://www.azpicentral.com/tagrisso/tagrisso.pdf Osimertinib (Tagrisso) package insert]<ref name="insert"></ref> | ||
| − | *[ | + | *[https://chemocare.com/druginfo/osimertinib.aspx Osimertinib (Tagrisso) patient drug information (Chemocare)]<ref>[https://chemocare.com/druginfo/osimertinib.aspx Osimertinib (Tagrisso) patient drug information (Chemocare)]</ref> |
*[http://www.uptodate.com/contents/osimertinib-patient-drug-information Osimertinib (Tagrisso) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/osimertinib-patient-drug-information Osimertinib (Tagrisso) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/osimertinib-patient-drug-information Osimertinib (Tagrisso) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/osimertinib-patient-drug-information Osimertinib (Tagrisso) patient drug information (UpToDate)]</ref> | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | *11 | + | *2015-11-13: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm472565.htm FDA granted accelerated approval] for the treatment of patients with metastatic [[Biomarkers#EGFR|epidermal growth factor receptor (EGFR)]] [[Biomarkers#T790M|T790M mutation-positive]] [[Non-small_cell_lung_cancer|non-small cell lung cancer (NSCLC)]], as detected by an FDA-approved test, who have progressed on or after [[Regimen_classes#EGFR_TKI_therapy|EGFR tyrosine kinase inhibitor (TKI) therapy]].<ref name="insert"></ref> ''(Based on AURA and AURA2)'' |
| − | * | + | **2017-03-30: [https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm549683.htm FDA granted regular approval] for the treatment of patients with metastatic [[Biomarkers#EGFR|epidermal growth factor receptor (EGFR)]] [[Biomarkers#T790M|T790M mutation-positive]] [[Non-small_cell_lung_cancer|non-small cell lung cancer (NSCLC)]], as detected by an FDA-approved test, who have progressed on or after [[Regimen_classes#EGFR_TKI_therapy|EGFR tyrosine kinase inhibitor (TKI) therapy]].<ref name="insert"></ref> ''(Based on AURA3)'' |
| − | * | + | *2018-04-18: [https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm605113.htm FDA approved] for the first-line treatment of patients with metastatic [[Non-small_cell_lung_cancer|non-small cell lung cancer (NSCLC)]] whose tumors have [[Biomarkers#EGFR|epidermal growth factor receptor (EGFR)]] [[Biomarkers#Exon_19|exon 19]] [[Biomarkers#Deletion|deletions]] or [[Biomarkers#L858R|exon 21 L858R mutations]]. ''(Based on FLAURA)'' |
| − | *12 | + | *2020-12-18: Approved for adjuvant therapy after tumor resection in patients with [[Non-small_cell_lung_cancer|non-small cell lung cancer (NSCLC)]] whose tumors have [[Biomarkers#EGFR|epidermal growth factor receptor (EGFR)]] [[Biomarkers#Exon_19|exon 19]] [[Biomarkers#Deletion|deletions]] or [[Biomarkers#L858R|exon 21 L858R mutations]]. ''(Based on ADAURA)'' |
| + | *2024-02-16: Approved with platinum-based chemotherapy for patients with locally advanced or metastatic [[non-small cell lung cancer]] (la/mNSCLC) whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. ''(Based on FLAURA2)'' | ||
| + | |||
| + | ==History of changes in EMA indication== | ||
| + | *2016-02-01: Initial marketing authorization as Tagrisso. | ||
| + | |||
| + | ==History of changes in Health Canada indication== | ||
| + | *2016-07-05: Initial notice of compliance with conditions | ||
| + | *2018-01-19: Conditions were met | ||
| + | |||
| + | ==History of changes in PMDA indication== | ||
| + | *2016-03-28: Initial approval for the treatment of inoperable or recurrent epidermal growth factor receptor (EGFR) T790M mutation-positive [[non-small cell lung cancer]] with resistance to EGFR tyrosine kinase inhibitors. | ||
| + | *2018-08-21: New indication for the treatment of inoperable or recurrent epidermal growth factor receptor (EGFR) mutation-positive [[non-small cell lung cancer]]. | ||
| + | *2022-08-24: New indication, a new dosage, and other characteristics for postoperative adjuvant treatment for epidermal growth factor receptor (EGFR) mutation-positive [[non-small cell lung cancer]]. | ||
==Also known as== | ==Also known as== | ||
| − | *'''Code name:''' | + | *'''Code name:''' AZD-9291 |
| − | *'''Brand name:''' Tagrisso | + | *'''Brand name:''' Osimert, Tagrisso, Tagrix |
==References== | ==References== | ||
| Line 39: | Line 52: | ||
[[Category:Non-small cell lung cancer medications]] | [[Category:Non-small cell lung cancer medications]] | ||
| + | [[Category:EMA approved in 2016]] | ||
[[Category:FDA approved in 2015]] | [[Category:FDA approved in 2015]] | ||
| + | [[Category:Health Canada approved in 2016]] | ||
| + | [[Category:PMDA approved in 2016]] | ||
Latest revision as of 12:00, 29 June 2024
General information
Class/mechanism: Mutant-selective EGFR tyrosine kinase inhibitor. Osimertinib preferentially binds irreversibly to certain mutant forms of the epidermal growth factor receptor (EGFR) (T790M, L858R, and exon 19 deletion) at approximately 9-times lower concentrations than wild-type. Two pharmacologically-active metabolites of osimertinib, AZ7550 and AZ5104, also emerge at about 10% the level of osimertinib. AZ7550 had similar potency to osimertinib. AZ5104 had about 8-times greater potency against exon 19 deletion and T790M mutants than osimertinib and 15-times greater potency against wild-type EGFR. Osimertinib also inhibits activity of HER2, HER3, HER4, ACK1, and BLK.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Resistance mechanisms
- 2019: Leonetti et al. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
Diseases for which it is used
Patient drug information
- Osimertinib (Tagrisso) package insert[1]
- Osimertinib (Tagrisso) patient drug information (Chemocare)[4]
- Osimertinib (Tagrisso) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 2015-11-13: FDA granted accelerated approval for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.[1] (Based on AURA and AURA2)
- 2017-03-30: FDA granted regular approval for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.[1] (Based on AURA3)
- 2018-04-18: FDA approved for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations. (Based on FLAURA)
- 2020-12-18: Approved for adjuvant therapy after tumor resection in patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations. (Based on ADAURA)
- 2024-02-16: Approved with platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer (la/mNSCLC) whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. (Based on FLAURA2)
History of changes in EMA indication
- 2016-02-01: Initial marketing authorization as Tagrisso.
History of changes in Health Canada indication
- 2016-07-05: Initial notice of compliance with conditions
- 2018-01-19: Conditions were met
History of changes in PMDA indication
- 2016-03-28: Initial approval for the treatment of inoperable or recurrent epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer with resistance to EGFR tyrosine kinase inhibitors.
- 2018-08-21: New indication for the treatment of inoperable or recurrent epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer.
- 2022-08-24: New indication, a new dosage, and other characteristics for postoperative adjuvant treatment for epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer.
Also known as
- Code name: AZD-9291
- Brand name: Osimert, Tagrisso, Tagrix